{"id":955223,"date":"2026-04-28T07:06:04","date_gmt":"2026-04-28T11:06:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/"},"modified":"2026-04-28T07:06:04","modified_gmt":"2026-04-28T11:06:04","slug":"avalo-therapeutics-purchases-optional-milestone-buyout","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/","title":{"rendered":"Avalo Therapeutics Purchases Optional Milestone Buyout"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WAYNE, Pa., April  28, 2026  (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX) (\u201cAvalo\u201d), a clinical-stage biotechnology company fully dedicated to developing IL-1\u03b2 based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the \u201cBuyout Agreement\u201d) related to the company\u2019s prior acquisition of AlmataBio, Inc. in March of 2024.<\/p>\n<p align=\"justify\">Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first patient being dosed in a Phase 3 trial.<\/p>\n<p align=\"justify\">\n        <strong>About Avalo Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1\u03b2-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We\u2019re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rwjCJATG8_ORjz70aiKmLHoYBkCEhmzJPwsYBKqFpzu8iYDhDhBeQlV5k60zvGcDKqVXUw_vkwpC5nV06OojhZVil6avCCeXl0o94Db6U28=\" rel=\"nofollow\" target=\"_blank\">www.avalotx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo\u2019s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo\u2019s plans, objectives, projections, expectations and intentions and other statements identified by words such as \u201cprojects,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201cseeks,\u201d \u201caims,\u201d \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpotential,\u201d or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo\u2019s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo\u2019s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.<\/p>\n<p align=\"justify\">\n        <strong>For media and investor inquiries<\/strong><br \/>\n        <br \/>Christopher Sullivan, CFO <br \/>Avalo Therapeutics, Inc. <br \/>ir@avalotx.com<br \/>410-803-6793<\/p>\n<p align=\"justify\">\n        <em>or<\/em>\n      <\/p>\n<p align=\"justify\">Meru Advisors<br \/>Lauren Glaser<br \/>lglaser@meruadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTUxYTZmNjYtNmIxNS00NTI3LWI5ZDEtZjJiNjFhYWE4MmEyLTEwMzA4OTMtMjAyNi0wNC0yOC1lbg==\/tiny\/Avalo-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX) (\u201cAvalo\u201d), a clinical-stage biotechnology company fully dedicated to developing IL-1\u03b2 based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the \u201cBuyout Agreement\u201d) related to the company\u2019s prior acquisition of AlmataBio, Inc. in March of 2024. Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avalo Therapeutics Purchases Optional Milestone Buyout&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955223","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX) (\u201cAvalo\u201d), a clinical-stage biotechnology company fully dedicated to developing IL-1\u03b2 based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the \u201cBuyout Agreement\u201d) related to the company\u2019s prior acquisition of AlmataBio, Inc. in March of 2024. Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first &hellip; Continue reading &quot;Avalo Therapeutics Purchases Optional Milestone Buyout&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T11:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avalo Therapeutics Purchases Optional Milestone Buyout\",\"datePublished\":\"2026-04-28T11:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/\"},\"wordCount\":473,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/\",\"name\":\"Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\",\"datePublished\":\"2026-04-28T11:06:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-purchases-optional-milestone-buyout\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avalo Therapeutics Purchases Optional Milestone Buyout\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/","og_locale":"en_US","og_type":"article","og_title":"Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk","og_description":"WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX) (\u201cAvalo\u201d), a clinical-stage biotechnology company fully dedicated to developing IL-1\u03b2 based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the \u201cBuyout Agreement\u201d) related to the company\u2019s prior acquisition of AlmataBio, Inc. in March of 2024. Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first &hellip; Continue reading \"Avalo Therapeutics Purchases Optional Milestone Buyout\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T11:06:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avalo Therapeutics Purchases Optional Milestone Buyout","datePublished":"2026-04-28T11:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/"},"wordCount":473,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/","name":"Avalo Therapeutics Purchases Optional Milestone Buyout - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=","datePublished":"2026-04-28T11:06:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzkwOCM3NTY4NzAyIzIwMTkzMjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-purchases-optional-milestone-buyout\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avalo Therapeutics Purchases Optional Milestone Buyout"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955223"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}